BACKGROUND: 24, 25(OH) 2 D] in serum may be both a nuisance and nutritionally valuable.
Within the vitamin D metabolism pathway, the 24-hydroxylase (CYP24A1) 8 2 D in the circulation is at the same time a nuisance and a clinically relevant value, highlighting the importance of its measurement in serum. In vitro experiments with purified CYP24A1 suggest that this 24-hydroxylation is just the first step in a 5-step, vitamin D-inducible pathway to water-soluble truncated degradation products (1 ) . Not unsurprisingly, assessment of serum 24,25(OH) 2 D, particularly when expressed as a molar ratio to 25(OH)D, has found favor as an index of vitamin D deficiency and catabolism in healthy individuals (2) (3) (4) (5) , as well as in those with rare genetic mutations in the CYP24A1 gene (5, 6 ) . The ratio of 24,25(OH) 2 D to 25(OH)D may also be an indicator of response to vitamin D supplementation (3 ) and may help to explain some of the well-documented interindividual differences in response of serum 25(OH)D to the same administered dose of vitamin D. Older data from animal experiments also suggest that 24,25(OH) 2 D [or the 24-hydroxylated product of 1,25(OH) 2 D 3 , 1,24,25(OH) 3 D 3 ] may stimulate intestinal calcium absorption and bone calcium mobilization (6, 7 ) . More recently, there is evidence for a role in fracture healing (8, 9 ) . Thus, the recent advancement of liquid chromatographic methods for measurement of serum 24,25(OH) 2 D (3 ), in some cases in par-allel with serum 25(OH)D (5 ) , is of note and should help address some of the knowledge gaps in relation to these putative roles of 24,25(OH) 2 D in human biology. Binkley and Wiebe (10 ) recently suggested that important challenges continue to vex the measurement of circulating 25(OH)D, despite this being recognized as the best clinical indicator of vitamin D status (11 ) . Although chromatography-based approaches are currently considered the research gold standard (12 ) , immunoassay procedures are in widespread clinical use (10 ) . The presence of 24,25(OH) 2 D, as well as other metabolites, in serum may contribute to the positive bias of some immunoassay-based methods relative to that of chromatography-based measurements (10, 13, 14 ) . Because 24,25(OH) 2 D may range from 2% to 20% of total serum total 25(OH)D (15 ), Binkley and Wiebe (10 ) illustrated its theoretical effect on 25(OH)D measurement and the inflation of the true 25(OH)D value. However, although these estimates are telling, they do not account for the fact that some commercial immunoassays cross-react Ͼ100% with 24,25(OH) 2 D (see Supplemental Table 1 , which accompanies the online version of this article at http://www.clinchem.org/content/ vol61/issue4). The UK Vitamin D External Quality Assurance Scheme (DEQAS) showed in 1 of their quarterly cycles in 2012 that different immunoassays overestimated serum total 25(OH)D by 144%-750% relative to a mean chromatographic estimate, when a single serum sample was spiked with 24S,25(OH) 2 D (personal communication from author G.D. Carter, October 2014). Of note, however, the 24R isomer is the physiologically relevant one, since the 24S isomer is not found in humans. Not unsurprisingly, gaining a better understanding of the contribution of 24,25(OH) 2 D to 25(OH)D measurement is an area that the Vitamin D Standardization Program (VDSP) has prioritized for further research (14 ) .
The objective of this work was to investigate the impact of 24R,25(OH) 2 D, at a physiologically relevant concentration, on the performance of a commercially available immunoassay for serum total 25(OH)D compared with that from a certified LC-MS/MS method, and to use this data to explore whether the 24,25(OH) 2 D concentration in serum of healthy adults from a nationally representative sample explains the positive bias in the immunoassay-based estimates of serum 25(OH)D concentrations (16 ) . Unpublished data from 6 recent cycles of DEQAS were used to test the bias of the most commonly used immunoassays in the scheme relative to the target serum 25(OH)D values as measured by NIST with and without adjustment for measured 24,25(OH) 2 D 3 concentration. Finally, the utility of serum 24,25(OH) 2 D 3 : 25(OH)D 3 as an index of inactivation and also of response to supplementation was further explored by use of data from a recent vitamin D RCT in older adults (4 ).
Participants and Methods

THE NATIONAL ADULT NUTRITION SURVEY SAMPLE
A detailed description of the participant sampling and recruitment procedures and methods of data collection used in the Irish National Adult Nutrition Survey (NANS) (n ϭ 1500) has been reported elsewhere (17, 18 ) . In the present work, data on serum 24, 25(OH) 2 D 3 concentration was available for a subset of NANS participants (n ϭ 134) in whom the impact of low and high calcium intake and low and high serum total 25(OH)D concentrations on serum 24,25(OH) 2 D 3 , as an index of vitamin D catabolism, was investigated. Thus, the data did not cover the full distribution of participants but rather those with the lowest and highest calcium intake/total 25(OH)D within the population, which is of particular use in the present study. Serum total 25(OH)D concentration data as measured by enzyme immunoassay (EIA) (Octeia ® 25-Hydroxy Vitamin D, Immuno Diagnostic Systems), and reported previously (18 ) , was also available for the current work.
THE VITAMIN D RANDOMIZED CONTROLLED TRIAL IN OLDER
ADULTS
The 15-week winter-based, randomized, placebocontrolled, double-blind vitamin D 3 intervention (20 g/day) study (which we will refer to in short as VitD-Ca RCT) has been described in detail elsewhere (4 ) . Study participants were free-living women and men (ratio approximately 2.5:1, age Ն50 years, n ϭ 125), stratified according to calcium intake (moderate-low, Ͻ700 mg/ day, or high, Ͼ1000 mg/day). The study was registered on ClinicalTrials.gov (identifier: NCT01990872). Serum total 25(OH)D and 24,25(OH) 2 D 3 increases and decreases, respectively, in the vitamin D 3 and placebo groups were of magnitudes similar to those with calcium intakes Ͻ700 and Ͼ1000 mg/day (4 ) . In the present study, since there was no interaction with dietary calcium (P ϭ 0.2), we examined the effect of vitamin D 3 We selected 4 baseline serum samples from the VitD-Ca RCT for measurement of serum total 25(OH)D by immunoassay (Octeia) before and after spiking the samples with the R isomer 24,25(OH) 2 Table 2 ). The increase in serum total 25(OH)D in spiked samples, as measured by immunoassay, ranged from 14 to 38 nmol/L and far exceeded the concentration of spiked or total (spike plus natural content) serum 24, 25(OH) 2 D 3 present (Table 2) Table 2) .
We also used the measured 24,25(OH) 2 D 3 concentration in sera from the NANS subset (with and without the mean factor of 2.79) to adjust the immunoassaymeasured total serum 25(OH)D concentration and compare the mean to that from LC-MS/MS estimates. Fig.  1A shows the significant positive bias (11.1%; P Ͻ 0.001) of the immunoassay-measured serum total 25(OH)D in the NANS subset samples compared with the equivalent measured by the LC-MS/MS procedure. Adjusting the immunoassay-measured estimates of total serum 25(OH)D for the measured 24,25(OH) 2 D 3 concentration in each sample lowered this mean bias (to 1.6%), which was not significant (P Ͼ 0.1). Also, the discrepancy at the level of individual samples was improved (Fig. 1B) , such that, for example, the percentage of samples with Ͼ20% absolute bias from LC-MS/MS values decreased from 35.4% to 14.6% for immunoassay unadjusted and adjusted for measured 24,25(OH) 2 D 3 concentration, respectively. When the mean antibody overreaction factor was applied, the original mean positive bias became an overall negative mean bias of about the same absolute magnitude (Ϫ15.2%; P Ͻ 0.001), and the discrepancy in the individual samples was even greater than unadjusted immunoassay values (Fig. 1C) . For example, the percentage of samples with Ͼ20% absolute bias from LC-MS/MS values increased (Table 3) . For the other 3 immunoassays, the positive bias of IDS EIA and Siemens ADVIA Centaur was improved to a more favorable quantitatively negative bias; for the Roche Total, the positive bias was reduced to a negative bias but of a greater magnitude (Table 3) . Fig. 1 ). There was no significant association in the placebo group (P ϭ 0.53) (data not shown). 2 Ͼ50 nmol/L (22 ), whereas a ratio above this suggests sufficiency.
Ratio of 24,25(OH)
The inverse association between serum 25(OH)D 3 : 24,25(OH) 2 D 3 and 25(OH)D 3 (R 2 ϭ 0.328) was much stronger than that between serum PTH and 25(OH)D 3 (R 2 ϭ 0.087) (Fig. 2, B and C, respectively) .
Discussion
The findings of the present study, which included data from 6 recent cycles of DEQAS and the returns for its 6 commonly used immunoassays, each representing Ͼ5% of all results returned in the DEQAS scheme (April 2014), clearly showed that adjustment for concentration of measured 24,25(OH) 2 D 3 in serum diminished the significant positive bias in measurement of serum total 25(OH)D by some immuno-based assays compared with LC-MS/MS. For other immunoassays, which had relatively small mean biases to begin with, it led to artificially larger negative biases. This simple analysis did not attempt to adjust for the fact that some of the antibodies cross-react with 24,25(OH) 2 D 3 by Ͼ100%.
We wished to explore further the nature of the impact of serum 24,25(OH) 2 D 3 on total serum 25(OH)D as measured by 1 of these commonly used commercial immuno-based assays, as it might explain, at least in part, the significant positive bias and underestimation of the prevalence of the population with serum 25(OH)D concentrations Ͻ30, Ͻ40, and Ͻ50 nmol/L, which we have reported previously when serum total 25(OH)D was measured in our nationally representative sample of adults by immunoassay compared with LC-MS/MS (16 ) . Adjustment of the immunoassay-derived serum total 25(OH)D value for the measured 24,25(OH) 2 D 3 concentration in serum in the present work showed that it brought the values closer to that measured by LC-MS/ MS, but the mean was still 17% higher. This might be expected because for some immunoassays, the antibody cross-reacts Ͼ100% with 24,25(OH) 2 D 3 , and simple adjustment for measured content will be an underestimation of its contribution to apparent total 25(OH)D.
DEQAS showed in 1 of their quarterly cycles in 2012 that different immunoassays overestimated serum total 25(OH)D by 144%-750% relative to a mean chromatographic estimate, when a single serum sample was spiked with 24,25(OH) 2 D at a single high concentration (57.9 nmol/L) and as the nonphysiologically relevant 24S isomer. Thus, to get better insight into the impact of the potential cross-reactivity with 24,25(OH) 2 D as the R isomer and at a more physiological concentration, we performed a relatively small, proof-of-principle spiking experiment. The data showed that for the 4 sera [25(OH)D range 24.1-38.9 nmol/L] spiked with 24R, 25(OH) 2 D 3 to achieve 6.3-7.5 nmol/L, the antibody in the immunoassay significantly overreacted to serum 24,25(OH) 2 D 3 relative to 25(OH)D. The mean increase in serum total 25(OH)D was such that the percentage cross-reactivity was on the order of Ͼ300%, but lower than the approximately 600% found in the 2012 DEQAS exercise with the 24S isomer. Although the result was in only 1 commercial assay, which is certainly a limitation of the current study, results of a very recent DEQAS investigation (unpublished data provided by G.D. Carter) has revealed very high cross-reactivity of 24R,25(OH) 2 D 3 in some, but not all, nonextraction and extraction immunoassays. This high degree of crossreactivity is a possible artifact associated with the spiking process. The anomalous behavior of exogenous 25(OH)D has also been reported (23 ) , although this metabolite was underrecovered in spiked samples. In addition, the independent spiking of the 4 same sera with 6.7 nmol/L 3-epimer of 25(OH)D 3 (which has been reported to have extremely low cross-reactivity) led to no increase in the immunoassay-measured total 25(OH)D in the present study, possibly suggesting that spiking artifacts are not the sole factor involved, something that will need to be tested and confirmed in additional work.
Whatever the underlying reason for this potentially anomalous behavior of exogenous 24R,25(OH) 2 D 3 in the present study and that of the recent DEQAS cycle, it may explain why adjusting for the 24,25(OH) 2 D 3 concentration and its overreactivity within our NANS dataset led to an exaggeration of the effect of 24,25(OH) 2 D 3 and resulted in an overall negative mean bias in 25(OH)D. However, the same crude correction factor applied to our 4 sera brought the estimates of serum total 25(OH)D from the immunoassay closer to that of the LC-MS/MS than did just adjustment for measured serum 24,25(OH) 2 D 3 concentration.
In relation to the purposeful measurement of serum 24,25(OH) 2 In that study, however, because of unavailability of baseline data, the ratio was from week 2 of the intervention and the change in serum 25(OH)D 3 was from week 2 to week 6 of intervention (3 ). These findings are likely related to the well-reported greater increase in serum 25(OH)D in individuals with lower baseline status (24 ) . In contrast to Wagner et al. (3 ) , who reported that the ratio was higher in vitamin D-supplemented women than men (young adults), at week 6 of their RCT, but not at week 2, there was no sex difference at baseline or end point (week 15) in our trial. Our data point to no difference in the rate of vitamin D catabolism in older adult men or women. In agreement with the findings of Wagner et al. (3 ) , the moderate inverse correlation with 24,25(OH) 2 In conclusion, the effect of 24,25(OH) 2 D 3 in serum-interferent for some immunoassays and yet potentially informative in terms of status-has been highlighted by the present findings. We support the view of the VDSP that further priority research is needed to gain a better understanding of the contribution of 24,25(OH) 2 D 3 to 25(OH)D measurement (14 ) , but also believe this additional research should explore the additional benefit, if any, of 24,25(OH) 2 D 3 and its molar ratios with 25(OH)D in terms of informing vitamin D status.
